Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Several smaller pharmaceutical companies
|
| gptkbp:advertising |
Aggressive marketing strategy
|
| gptkbp:awards |
Multiple industry awards
|
| gptkbp:businessModel |
Vertical integration
|
| gptkbp:CEO |
Xie_Yi
|
| gptkbp:certifications |
GMP_certified
|
| gptkbp:clinicalTrials |
Conducts clinical trials
|
| gptkbp:collaborations |
Academic institutions
|
| gptkbp:community_involvement |
Engaged in community health initiatives
|
| gptkbp:customerBase |
Diverse customer base
|
| gptkbp:employees |
Over 10,000
|
| gptkbp:exportedTo |
Products to over 100 countries
|
| gptkbp:financialPerformance |
Consistent growth
|
| gptkbp:financials |
Attracts significant investment
|
| gptkbp:founded |
1992
|
| gptkbp:future_plans |
Increase production capacity
Expand into new markets Enhance digital transformation Enhance R&D capabilities Expand international market Develop new drug formulations Invest in biotechnology |
| gptkbp:global_presence |
Strong global presence
|
| gptkbp:headquarters |
gptkb:Jinan,_Shandong,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Qilu Group
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:innovation |
Focus on innovation
|
| gptkbp:investmentFocus |
Significant investments in R&D
|
| gptkbp:market |
Global
Significant_market_share_in_China |
| gptkbp:notableEvent |
High product quality standards
|
| gptkbp:partnerships |
Various global partners
Various international pharmaceutical companies |
| gptkbp:patentCitation |
Numerous patents in pharmaceuticals
|
| gptkbp:productionLocation |
Several manufacturing facilities
|
| gptkbp:productLine |
Diverse product lines
|
| gptkbp:products |
OTC drugs
Vaccines Prescription drugs Formulations Biopharmaceuticals Active pharmaceutical ingredients |
| gptkbp:regulatoryCompliance |
Meets international regulations
|
| gptkbp:research_areas |
Multiple_R&D_centers
|
| gptkbp:researchAndDevelopment |
Strong focus
|
| gptkbp:revenue |
Over $1 billion
|
| gptkbp:social_responsibility |
Active CSR programs
|
| gptkbp:subsidiary |
Qilu_Pharmaceutical_Co.,_Ltd.
|
| gptkbp:supplyChain |
Robust supply chain
|
| gptkbp:sustainability_initiatives |
Active sustainability programs
|
| gptkbp:training |
Comprehensive training programs
|
| gptkbp:website |
www.qilugroup.com
|